Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.,STEM CELLS Translational Medicine

当前位置： X-MOL 学术 › Stem Cells Transl. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.
STEM CELLS Translational Medicine ( IF 5.4 ) Pub Date : 2020-04-12 , DOI: 10.1002/sctm.19-0424
Ingrid W Caras ₁

Affiliation

A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.

中文翻译：

从癌症干细胞模型的角度来看，在临床试验中有两种针对癌症干细胞的疗法。

癌症干细胞模型的关键含义是，要使癌症治疗有效，必须消除驱动肿瘤进展的癌症干细胞（CSC）。加州再生医学研究所正在支持两种针对CSC的新方法，一种是针对CD47的抗体介导的免疫疗法，另一种针对ROR1的抗体。本文总结了针对CSC的证据，并讨论了在CSC模型范围内进行早期临床试验的结果。

更新日期：2020-04-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11